Groupe Hospitalier Henri Mondor - Albert Chenevier

corporate_fareorganization

Groupe Hospitalier Henri Mondor - Albert Chenevier

- Funding / Projects
  (85)

85 Projects, page 1 of 17

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant
assignment_turned_inProjectPartners:HUS, Groupe Hospitalier Pitié Salpétrière, HUG, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Poitiers +10 partners
HUS,
Groupe Hospitalier Pitié Salpétrière,
HUG,
Hôpital Claude Huriez,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Toulouse,
Centre Hospitalier Universitaire de Limoges,
Institut Paoli-Calmettes- (IPC),
CHRU MTP,
Hôpital Necker- Enfants malades,
HCL,
Institut de cancérologie Lucien Neuwirth,
CHU Nantes - Hôtel Dieu,
CHU,
Groupe Hospitalier Henri Mondor - Albert Chenevier
Funder: Institut National du Cancer Project Code: INCa-DGOS-11089
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Clinical phase II trial evaluating the efficacy of systemic Mesenchymal Stromal Cell (MSC) injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications (pelvic radiation disease, PRD) refractory to standard therapy. Acronym : PRISME (Pelvic Radiation dISease and MEsenchymal stromal cells)
assignment_turned_inProjectPartners:Groupe Hospitalier Pitié Salpétrière, Centre René Gauducheau, Groupe Hospitalier Lariboisière - Fernand Widal, Hôpital Saint-Antoine, Institut de Radioprotection et de Sûreté Nucléaire +6 partners
Groupe Hospitalier Pitié Salpétrière,
Centre René Gauducheau,
Groupe Hospitalier Lariboisière - Fernand Widal,
Hôpital Saint-Antoine,
Institut de Radioprotection et de Sûreté Nucléaire,
Hôpital Européen Georges Pompidou (HEGP) - AP-HP,
Hôpital Saint-Louis,
U1018, INSERM, UPS, UVSQ Institut Gustave Roussy – B2M,
Société Française de Bio Ingenierie Cellulaire et Tissulaire,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Institut Gustave Roussy
Funder: Institut National du Cancer Project Code: INCa-DGOS-7278
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Radiation-induced sarcoma: predictive study based on the CONTICANET sarcomas registry.
assignment_turned_inProjectPartners:Centre Léon Bérard, Centre Antoine Lacassagne, Centre Paul Strauss, Groupe Hospitalier Henri Mondor - Albert Chenevier, CHU Marseille - Hôpital la Timone +5 partners
Centre Léon Bérard,
Centre Antoine Lacassagne,
Centre Paul Strauss,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
CHU Marseille - Hôpital la Timone,
Centre Georges-François Leclerc,
Institut Gustave Roussy,
Centre Oscar Lambret,
Institut de Cancérologie de Lorraine,
INSERM U916
Funder: Institut National du Cancer Project Code: INCa-DGOS-3770
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.
assignment_turned_inProjectPartners:Hôpital le Bocage, Groupe Hospitalier Henri Mondor - Albert Chenevier, Centre Hospitalier Régional et Universitaire de Lille, Centre Henri Becquerel, HCL +1 partners
Hôpital le Bocage,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Centre Hospitalier Régional et Universitaire de Lille,
Centre Henri Becquerel,
HCL,
CHLS
Funder: Institut National du Cancer Project Code: INCa-DGOS-337
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Grief of cancer patients' spouses: evaluation and subjective experience.
assignment_turned_inProject2011 - 2013Partners:Institut Curie, Groupe Hospitalier Henri Mondor - Albert Chenevier, UNIVERSITE RENE DESCARTES PARIS 5
Institut Curie,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
UNIVERSITE RENE DESCARTES PARIS 5
Funder: Institut National du Cancer Project Code: INCa-4699
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

Groupe Hospitalier Henri Mondor - Albert Chenevier

Groupe Hospitalier Henri Mondor - Albert Chenevier

85 Projects, page 1 of 17

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

Radiation-induced sarcoma: predictive study based on the CONTICANET sarcomas registry.

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

Grief of cancer patients' spouses: evaluation and subjective experience.

Loading